MATINAS BIOPHARMA HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 12.76 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-13
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 309.00 shares.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 12.45K shares, a 301.45% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 0.00 shares.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 3.10K shares, a 98.36% decline from fiscal 2024.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 188.62K shares, a 3083.96% increase from fiscal 2023.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 5.92K shares, a 96.61% decline from fiscal 2022.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 175.00K shares, a 93.80% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 309.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 12.76K shares 10-Q · filed 2026-08-13 | 12.76K shares derived: sum of 3 quarters · filed 2026-08-13 | 12.76K shares derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | 12.45K shares 10-Q · filed 2026-05-08 | 12.45K shares derived: sum of 2 quarters · filed 2026-05-08 | 12.45K shares derived: sum of 3 quarters · filed 2026-05-08 | 12.45K shares derived: sum of 4 quarters · filed 2026-05-08 | |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-31 | 0.00 shares derived: sum of 3 quarters · filed 2026-03-31 | 3.10K shares 10-K · filed 2026-03-31 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-10 | 3.10K shares 10-Q · filed 2025-11-10 | 173.07K shares derived: sum of 4 quarters · filed 2026-03-31 | |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 3.10K shares 10-Q · filed 2025-08-14 | 173.07K shares derived: sum of 3 quarters · filed 2026-03-31 | ||
| 2025-03-31 | 3.10K shares 10-Q · filed 2025-05-15 | 173.07K shares derived: sum of 2 quarters · filed 2026-03-31 | |||
| 2024-12-31 | 169.97K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 188.62K shares 10-K · filed 2026-03-31 | |||
| 2024-09-30 | 18.65K shares 10-Q · filed 2024-11-13 | ||||
| 2023-12-31 | -290.08K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -215.08K shares derived: sum of 2 quarters · filed 2025-04-15 | -75.08K shares derived: sum of 3 quarters · filed 2025-04-15 | 5.92K shares 10-K · filed 2025-04-15 | 296.00K shares 10-K · filed 2024-03-27 |
| 2023-09-30 | 75.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 215.00K shares derived: sum of 2 quarters · filed 2023-11-08 | 296.00K shares 10-Q · filed 2023-11-08 | 306.00K shares derived: sum of 4 quarters · filed 2024-03-27 | |
| 2023-06-30 | 140.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 221.00K shares 10-Q · filed 2023-08-09 | 231.00K shares derived: sum of 3 quarters · filed 2024-03-27 | 242.00K shares derived: sum of 4 quarters · filed 2024-03-27 | |
| 2023-03-31 | 81.00K shares 10-Q · filed 2023-05-10 | 91.00K shares derived: sum of 2 quarters · filed 2024-03-27 | 102.00K shares derived: sum of 3 quarters · filed 2024-03-27 | 156.00K shares derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-12-31 | 10.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | 21.00K shares derived: sum of 2 quarters · filed 2024-03-27 | 75.00K shares derived: sum of 3 quarters · filed 2024-03-27 | 175.00K shares 10-K · filed 2024-03-27 | |
| 2022-09-30 | 11.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | 65.00K shares derived: sum of 2 quarters · filed 2022-11-02 | 165.00K shares 10-Q · filed 2022-11-02 | ||
| 2022-06-30 | 54.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 154.00K shares 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 100.00K shares 10-Q · filed 2022-05-12 | ||||
| 2021-12-31 | 2.82M shares 10-K · filed 2023-03-15 | ||||
| 2020-12-31 | 0.00 shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | 0.00 shares derived: sum of 2 quarters · filed 2022-03-11 | 0.00 shares derived: sum of 3 quarters · filed 2022-03-11 | 72.00K shares 10-K/A · filed 2022-03-11 | |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-06 | 72.00K shares 10-Q · filed 2020-11-06 | ||
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 72.00K shares 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | 72.00K shares 10-Q · filed 2020-05-11 | ||||
| 2015-09-30 | 6.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | 74.44K shares derived: sum of 2 quarters · filed 2015-11-10 | 119.86K shares 10-Q · filed 2015-11-10 | 214.94K shares derived: sum of 4 quarters · filed 2015-11-10 | |
| 2015-06-30 | 67.78K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | 113.19K shares 10-Q · filed 2015-08-13 | 208.28K shares derived: sum of 3 quarters · filed 2015-08-13 | ||
| 2015-03-31 | 45.42K shares 10-Q · filed 2015-05-15 | 140.50K shares derived: sum of 2 quarters · filed 2015-05-15 | |||
| 2014-12-31 | 95.08K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | 196.00K shares 10-K · filed 2015-03-31 | |||
| 2014-09-30 | 100.92K shares 10-Q · filed 2014-11-14 | ||||
| 2013-12-31 | 0.00 shares 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |